secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000950170-24-052094
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences Q1 revenue $19.3M (+2% YoY); wins $34M jury verdict against Alcon
--------------------------------------------------------------------------------

- Q1 2024 revenue $19.3M (+2% YoY); Surgical Glaucoma $18.3M (+5%), Dry Eye $1.0M (-32%).
- Net loss $16.3M ($0.33/share) vs $17.1M ($0.35/share); gross margin 86% vs 84% prior year.
- Jury found willful infringement by Alcon; awards $5.5M lost profits + $28.5M royalty for Hydrus Microstent.
- Reaffirms FY2024 revenue guidance $81M-$85M (0-5% growth) and adjusted op ex $107M-$110M.
- Cash burn reduced to $10.8M (incl. $3.2M debt restructuring costs) from $17.7M in Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000095017024052094/0000950170-24-052094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000095017024052094/sght-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-052094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer